Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells

Patent metadata

Field	Value
Publication number	US-10188630-B2
Application number	US-201715712849-A
Country	US
Kind code	B2
Filing date	Sep 22, 2017
Priority date	Apr 6, 2010
Publication date	Jan 29, 2019
Grant date	Jan 29, 2019

Abstract

In one aspect, the invention provides a method for inhibiting the growth and/or proliferation of a myc-driven tumor cell comprising the step of contacting the tumor cells with a CSNK1ε inhibitor. In another aspect, the invention provides a method of treating a subject suffering from a tumor comprising myc-driven tumor cells, comprising administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.

First claim

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. A method of treating a subject having a tumor comprising tumor cells of neural origin that overexpress Myc, comprising:
determining that the tumor comprises tumor cells that overexpress Myc; and
then administering to the subject an amount of a composition comprising a CSNK1ε inhibitor effective to inhibit the growth and/or proliferation of the tumor cells.

2. The method of claim 1 , wherein the tumor is a primary neuroblastoma tumor, a metastatic neuroblastoma tumor, or a brain tumor.

3. The method of claim 1 , wherein the tumor is a primary neuroblastoma tumor or a metastatic neuroblastoma tumor.

4. The method of claim 1 , wherein the subject is further provided one or more additional anti-cancer therapies.

5. The method of claim 4 , wherein the additional anti-cancer therapy comprises chemotherapy.

6. The method of claim 5 , wherein the tumor cells that overexpresses Myc are resistant to cisplatin, and the CSNK1ε inhibitor renders the cell susceptible to cisplatin.

7. The method of claim 1 , wherein the CSNK1ε inhibitor is a small molecule inhibitor.

8. The method of claim 7 , wherein the CSNK1ε inhibitor is selected from the group consisting of IC261, PF-4800567, and PF-670462.

9. The method of claim 1 , wherein the Myc is c-Myc or MycN.

Assignees

• Hutchinson Fred Cancer Res

Inventors

• Grandori Carla
• Toyoshima Masafumi

Classifications

• A61K31/404 Primary

  Indoles, e.g. pindolol · CPC title

• A61K31/506

  not condensed and containing further heterocyclic rings · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K33/24

  Heavy metals; Compounds thereof · CPC title